Syndax Announces Data From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia Selected As Late-Breaking Presentation At The 65th ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals announced that data from its pivotal AUGMENT-101 trial of Revumenib for treating relapsed/refractory KMT2Ar acute leukemia has been selected for a late-breaking presentation at the 65th ASH Annual Meeting.
November 21, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals' announcement about the AUGMENT-101 trial data being presented at the ASH Annual Meeting could positively influence investor sentiment and potentially increase the stock price in the short term.
Presentations at major medical meetings like ASH can significantly impact a biopharmaceutical company's stock price as they provide critical updates on drug development progress. Positive data can lead to increased investor confidence and anticipation of future regulatory milestones, which can drive up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100